2C-I: Difference between revisions
From Pharmacopedia
More actions
| [pending revision] | [pending revision] |
MDElliottMD (talk | contribs) Category taxonomy ship: retag Research Materials -> Research chemicals |
MDElliottMD (talk | contribs) home-claude: Erowid dosing (erowid-claude source; URLs verified; em-dash clean) |
||
| Line 21: | Line 21: | ||
| indications = | | indications = | ||
| dosing = | | dosing = | ||
<titration slug="erowid-dose-oral" author="erowid-claude" | |||
title="Oral dose ladder (Erowid)"> | |||
Erowid's dosage documentation for oral 2C-I<ref name="erowid-2ci-dose"> | |||
Erowid. 2C-I Dosage. Erowid.org. | |||
https://www.erowid.org/chemicals/2ci/2ci_dose.shtml. | |||
Accessed 2026-05-25.</ref> reports the following tiers: | |||
* '''Threshold:''' 2-5 mg | |||
* '''Light:''' 5-15 mg | |||
* '''Common:''' 10-25 mg | |||
* '''Strong:''' 20-30 mg | |||
Heavy tier and timing data are not provided by Erowid. Erowid notes that | |||
2C-I is chemically distinct from the 2C-I-NBOMe compound despite similar | |||
naming. | |||
</titration> | |||
| effects = | | effects = | ||
| interactions = <pharmaInteractions/> | | interactions = <pharmaInteractions/> | ||